Method of co-expressing galactosyltransferase and a glycoprotein in a transgenic plant cell and sialylating the glycoprotein for production of glycoprotein having human-type sugar chain
A method for the secretory production of a glycoprotein having a human-type sugar chain, comprising a step of introducing a gene of an enzyme capable of performing a transfer reaction of a galactose residue to a non-reducing terminal acetylglucosamine residue, and a gene of heterologous glycoprotein, to obtain a transformed plant cell, a step of culturing the plant cell, and a step of recovering the culture medium of the plant cell. The method further includes isolating the glycoprotein from the culture medium and contacting the isolated glycoprotein with a sialic acid transferase to add a sialic acid residue attached to the galactose residue in the N-glycan.
1. A method for producing a secretory glycoprotein having a human-type sugar chain from a transgenic plant cell, the method comprising:
providing a transgenic plant cell that comprises a first heterologous nucleic acid sequence encoding a β1,4-galactosyltransferase, and a second heterologous nucleic acid sequence encoding a glycoprotein that is heterologous to the plant cell,
culturing the transgenic plant cell in a culture medium to allow production and secretion of the glycoprotein, which contains an N-glycan having a galactose residue linked to a non-reducing terminal acetylglucosamine residue;
isolating the glycoprotein from the culture medium; and
contacting the isolated glycoprotein with a sialic acid transferase to add a sialic acid residue attached to the galactose residue in the N-glycan.
2. The method of claim 1 , wherein in the transgenic plant cell, the expression of an endogenous β1,2-xylosyltransferase, α1,3-fucosyltransferase, or both is inhibited or a gene encoding the endogenous β1,2-xylosyltransferase or α1,3-fucosyltransferase is mutated.
3. The method of claim 2 , wherein the transgenic plant cell has the endogenous gene encoding the β1,2-xylosyltransferase or the endogenous α1,3-fucosyltransferase inactivated.
4. The method of claim 2 , wherein the transgenic plant cell has the endogenous genes encoding both the β1,2-xylosyltransferase and the α1,3-fucosyltransferase inactivated.
5. The method of claim 1 , wherein the culture medium comprises an agent that increases the concentration of the glycoprotein in the culture medium, and wherein the agent is polyvinylpyrrolidone (PVP).
6. The method of claim 5 , wherein the culture medium further comprises a protease inhibitor.
7. The method of claim 1 , wherein the transgenic plant cell is in a cultured plant tissue, a cultured plant organ, or a whole plant.
8. The method of claim 1 , wherein the transgenic plant cell is a cell of Solanaceae, Gramineae, Cruciferae, Rosaceae, Leguminosae, Cucurbitaceae, Labiatae, Liliaceae, Chenopodiaceae, or Umbelliferae.
9. The method of claim 8 , wherein the transgenic plant cell is a tobacco cell.
10. The method of claim 1 , wherein the heterologous glycoprotein is an enzyme, a hormone, a cytokine, an antibody, a vaccine antigen, a receptor, or a serum protein.
11. The method of claim 1 , wherein the β1,4-galactosyltransferase is a human β1,4-galactosyltransferase.
12. The method of claim 11 , wherein the human β1,4-galactosyltransferase comprises the amino acid sequence of SEQ ID NO:6.
13. The method of claim 1 , wherein the providing step is performed by:
introducing into a plant cell the first heterologous nucleic acid sequence and the second heterologous nucleic acid sequence; thereby producing the transgenic plant cell.
14. The method of claim 13 , wherein the providing step further comprises inactivating the endogenous β1,2-xylosyltransferase, α1,3-fucosyltransferase, or both in the plant cell.
15. The method of claim 14 , wherein the inactivating step is performed by chemical mutagenesis, site-directed mutagenesis, or a tagging method to inactivate the gene encoding the β1,2-xylosyltransferase or α1,3-fucosyltransferase.